Subtype
Malignant Uterine Neoplasm
CI-CAN-00005955Explore in graph →
824 active trials7 approved drugs44 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005955Explore in graph →
Clinical trials
3,291 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (333)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07172217 | The Efficacy and Safety RC48 Plus QL1706 in Second-Line Treatment of HER2-Expressing Recurrent CC | not yet recruiting | Phase 2 | 33 | Qilu Hospital of Shandong UniversityOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT07170982 | Fruquintinib Combined With Standard Chemotherapy Versus Standard Chemotherapy as First-line Treatment for Advanced pMMR Endometrial Cancer | not yet recruiting | Phase 2 | 128 | Sun Yat-sen UniversityOTHER | 1 | Sep 12, 2025 |
| NCT07055399 | Neoadjuvant Iparomlimab and Tuvonralimab Plus Chemotherapy-eclipse for Locally Advanced Cervical Cancer (NICE-CC)(NICE-CC) | recruiting | Phase 2 | 43 | Fujian Cancer HospitalOTHER_GOV | 1 | Sep 11, 2025 | clinicaltrials |
| NCT04646005 | Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy | completed | Phase 2 | 113 | Regeneron PharmaceuticalsINDUSTRY | 8 | Sep 8, 2025 | clinicaltrials |
| NCT00924027 | A Study of Patients Receiving High-Dose Rate Brachytherapy | completed | Phase 2 | 43 | National Cancer Institute (NCI)NIH | 1 | Sep 5, 2025 | clinicaltrials |
| NCT05462379 | Autologous Heterotopic Fresh Ovarian Graft in Woman With LACC Eligible for Pelvic Radiotherapy Treatment. | active not recruiting | Phase 1 / Phase 2 | 22 | MARILIA ALBANEZI BERTOLAZZIOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT07153952 | RT for Adenocarcinoma/Adenosquamous Carcinoma | active not recruiting | Phase 1 / Phase 2 | 60 | Peking Union Medical College HospitalOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT03300557 | Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Aug 29, 2025 | clinicaltrials |
| NCT07141186 | QL1706 in Patients With Recurrent and Metastatic Cervical Cancer Resistant to Prior PD-1/PD-L1 Antibody Therapy | not yet recruiting | Phase 2 | 50 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Aug 26, 2025 | clinicaltrials |
| NCT04080284 | Trial of Maintenance With Niraparib- Uterine Serous Carcinoma | completed | Phase 2 | 22 | Northwell HealthOTHER | 1 | Aug 19, 2025 | clinicaltrials |
| NCT07115927 | pReOperative Dostarlimab and Novel Therapies in EndOmetrial Cancer(RODEO) | not yet recruiting | Phase 2 | 40 | University College, LondonOTHER | 0 | Aug 19, 2025 | clinicaltrials |
| NCT07130240 | Ivonescimab Combined With Paclitaxel and Cisplatin as Neoadjuvant Therapy Followed by Type A Hysterectomy in Stage IB2 and IIA1 Cervical Cancer | recruiting | Phase 2 | 20 | Obstetrics & Gynecology Hospital of Fudan UniversityOTHER | 1 | Aug 19, 2025 | clinicaltrials |
| NCT00788671 | Levonorgestrel-Releasing Intrauterine System in Treating Patients With Complex Atypical Hyperplasia or Grade I Endometrial Cancer | active not recruiting | Phase 2 | 69 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 15, 2025 | clinicaltrials |
| NCT06321068 | BAT1308 in Combination With Platinum-containing Chemotherapy is Used for the First-line Treatment of Advanced or Recurrent dMMR Endometrial Cancer | terminated | Phase 2 / Phase 3 | 5 | Bio-Thera SolutionsINDUSTRY | 1 | Aug 14, 2025 | clinicaltrials |
| NCT03314935 | A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors | completed | Phase 1 / Phase 2 | 149 | Incyte CorporationINDUSTRY | 3 | Aug 12, 2025 | clinicaltrials |
| NCT04159155 | A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer(CAN-STAMP) | terminated | Phase 2 / Phase 3 | 11 | University Health Network, TorontoOTHER | 1 | Aug 12, 2025 | clinicaltrials |
| NCT04491643 | Megestrol Acetate Plus Rosuvastatin in Young Women With Early Endometrial Carcinoma | completed | Phase 2 | 48 | Fudan UniversityOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT05057013 | A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours | active not recruiting | Phase 1 / Phase 2 | 81 | Cancer Research UKOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT07104149 | Neoadjuvant Chemotherapy Plus Cadonilimab for Locally Advanced Cervical Cancer | recruiting | Phase 2 | 29 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Aug 5, 2025 | clinicaltrials |
| NCT01979393 | IRCI Gynae Sarcomas, High Grade Uterine Sarcoma | completed | Phase 2 | 58 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 5 | Aug 1, 2025 | clinicaltrials |
| NCT03395080 | A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or Carcinosarcoma(P204) | completed | Phase 2 | 111 | Leap Therapeutics, Inc.INDUSTRY | 1 | Aug 1, 2025 | clinicaltrials |
| NCT02730429 | Trial of Letrozole + Palbociclib/Placebo in Metastatic Endometrial Cancer | completed | Phase 2 | 78 | Nordic Society of Gynaecological Oncology - Clinical Trials UnitOTHER | 1 | Jul 31, 2025 | clinicaltrials |
| NCT05017246 | Comparing Intrathecal Morphine and Intraoperative Lidocaine Infusion to Epidural Anesthesia With Postoperative PCA for Patients Undergoing Exploratory Laparotomy | terminated | Phase 2 | 110 | Washington University School of MedicineOTHER | 1 | Jul 31, 2025 | clinicaltrials |
| NCT03104699 | A Study of AGEN2034 in Advanced Tumors and Cervical Cancer | completed | Phase 1 / Phase 2 | 211 | Agenus Inc.INDUSTRY | 9 | Jul 30, 2025 | clinicaltrials |
| NCT03444376 | The Combination of GX-188E Vaccination and Pembrolizumab in Patients With HPV 16 and/or 18+ Advanced Cervical Cancer | completed | Phase 1 / Phase 2 | 65 | Genexine, Inc.INDUSTRY | 1 | Jul 30, 2025 | clinicaltrials |
| NCT07092696 | Induction Immunotherapy Combined With Chemotherapy Followed by Concurrent Chemoradiotherap and Immunotherapy for Cervical Cancer | recruiting | Phase 2 | 34 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT02730416 | Combination Chemotherapy With Nintedanib / Placebo in Endometrial Cancer | completed | Phase 2 | 146 | Nordic Society of Gynaecological Oncology - Clinical Trials UnitOTHER | 7 | Jul 29, 2025 | clinicaltrials |
| NCT03086681 | Endostar Combined With Concurrent Chemoradiotherapy For Locally Advanced Cervical Carcinoma(ECWHCCFLACC) | completed | Phase 2 | 120 | Yong Zhang,MDOTHER | 1 | Jul 29, 2025 | clinicaltrials |
| NCT06277154 | MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma | recruiting | Phase 2 | 148 | HRYZ Biotech Co.INDUSTRY | 1 | Jul 24, 2025 | clinicaltrials |
| NCT04577963 | A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 52 | HutchmedINDUSTRY | 1 | Jul 14, 2025 | clinicaltrials |
| NCT05563272 | 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors(STARBURST) | terminated | Phase 2 | 11 | Telix Pharmaceuticals (Innovations) Pty LtdINDUSTRY | 1 | Jul 10, 2025 | clinicaltrials |
| NCT02611024 | Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors | completed | Phase 1 / Phase 2 | 316 | PharmaMarINDUSTRY | 6 | Jul 9, 2025 | clinicaltrials |
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study(ABILITY-1) | recruiting | Phase 1 / Phase 2 | 115 | Medicenna Therapeutics, Inc.INDUSTRY | 7 | Jul 9, 2025 | clinicaltrials |
| NCT06942377 | Calcium Channel Blocker Amlodipine for Endometrial Cancer Therapy | not yet recruiting | Phase 2 | 140 | Peking University People's HospitalOTHER | 1 | Jul 8, 2025 | clinicaltrials |
| NCT02635360 | Pembrolizumab and Chemoradiation Treatment for Advanced Cervical Cancer | completed | Phase 2 | 94 | Linda R DuskaOTHER | 1 | Jul 3, 2025 | clinicaltrials |
| NCT03357757 | Avelumab With Valproic Acid in Virus-associated Cancer(LATENT) | completed | Phase 2 | 39 | AHS Cancer Control AlbertaOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT07003620 | Neoadjuvant Immunochemotherapy for Locally Advanced Cervical Cancer: a Prospective, Single-arm, Phase II Clinical Trial | recruiting | Phase 2 | 34 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jun 17, 2025 | clinicaltrials |
| NCT02899793 | Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer | completed | Phase 2 | 25 | Yale UniversityOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT06073184 | Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Low-grade Cancer of the Endometrium(WE-FiERCE) | not yet recruiting | Phase 2 | 71 | University Health Network, TorontoOTHER | 0 | Jun 10, 2025 | clinicaltrials |
| NCT06393751 | Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Jun 3, 2025 | clinicaltrials |
| NCT06998394 | A Single-Arm, Phase II Clinical Trail of Cadonilimab Combined With Chemoradiotherapy in Oligometastatic Stage IVB Cervical Cancer | recruiting | Phase 2 | 30 | Xiangbo WanOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT03101995 | Assessment of Gemcitabine as Chemoradiotherapy in Patients With Locally Advanced Carcinoma of Cervix and Renal Disease | recruiting | Phase 2 | 18 | National Institute of CancerologíaOTHER_GOV | 1 | May 28, 2025 | clinicaltrials |
| NCT03108131 | Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors | completed | Phase 2 | 49 | M.D. Anderson Cancer CenterOTHER | 1 | May 28, 2025 | clinicaltrials |
| NCT04574284 | A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer | completed | Phase 2 | 170 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | May 28, 2025 | clinicaltrials |
| NCT02713386 | Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 1 / Phase 2 | 147 | NRG OncologyOTHER | 1 | May 25, 2025 | clinicaltrials |
| NCT04513665 | ZW25 in Women With Endometrial Cancers | completed | Phase 2 | 16 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 22, 2025 | clinicaltrials |
| NCT06986057 | Iparomlimab and Tuvonralimab Combined With Platinum-Based Chemotherapy for Neoadjuvant Treatment of Cervical Cancer | not yet recruiting | Phase 2 | 28 | Shandong Tumor HospitalOTHER | 0 | May 22, 2025 | clinicaltrials |
| NCT06981858 | A Single-Arm Exploratory Study of Enlansibumab Sequentially Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer | not yet recruiting | Phase 2 | 34 | Chongqing University Cancer HospitalOTHER | 0 | May 21, 2025 | clinicaltrials |
| NCT03255252 | Assessment Study to Evaluate Specific Immune Response in Locally Advanced Cervix Cancer After Radio-chemotherapy(IMMUVIX) | terminated | Phase 2 | 29 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | May 18, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Sep 15, 2025source: clinicaltrials